|
(Health-NewsWire.Net, June 20, 2015 ) ALBANY, New York, June 19, 2015:- ResearchMoz has recently added the “Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition” report to its vast database of research reports.The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Orphan Drugs Market in Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget limitations, and growing demands for evidence of clinical and cost effectiveness?
Payers are becoming increasingly strict. Four of the first seven orphan drugs to enter Germany’s AMNOG procedure were considered to bring only minor additional benefit and for two others the benefit was deemed non-quantifiable. Discounts were required for all. Re-evaluation by the Transparency Commission in France has seen both SMR and ASMR scores downgraded with resultant price cuts. Half of all orphan drugs evaluated have been rejected by one or more HTA bodies in the UK.
Manufacturers of treatments for Fabry and Pompe diseases are currently negotiating discounts in the Netherlands to prevent delisting after results from a four-year conditional reimbursement PMS period disappointed. On a more positive note, September 2013 saw the start of the first pilot pan-EU assessment under the Mechanism of Co-ordinated Access to Orphan Medicinal Products (MoCA-OMP) initiative.
Request a Sample Copy of the Report @ http://www.researchmoz.us/enquiry.php?type=sample&repid=175644 .
Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access, 2013 Edition is a fully revised and greatly enlarged version of Justpharmareports best-selling 2008 and 2011 reports, and the author’s sixth major title on the subject.
Updated to autumn 2013, it includes:
Availability, price and reimbursement status for all 64 EU-designated orphan drugs as of June 2013 with centralised marketing authorisations granted prior to end-2012.
How orphan drug policies differ across Europe. Expanded sections on each EU-5 country, Belgium, Netherlands and Sweden. 25 countries covered in total.
Both hospital and out-of-hospital market segments.
How reimbursement systems treat orphan drugs. ‘High cost’ funding systems explained.
Impact of health technology assessment.
How managed entry agreements and patient registries can help bridge the data gap.
Key role of patient advocacy groups.
15 case studies.
The potential for European collaboration to accelerate market access.
Browse Complete Report with TOC @ http://www.researchmoz.us/orphan-drugs-in-europe-pricing-reimbursement-funding-and-market-access-issues-2013-edition-report.html .
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact
Mr. Nachiket
90 State Street,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-618-1030
sales@researchmoz.us
Source: EmailWire.Com 
|
